GB2426517A - Methods and agents for inhibiting dynamin-dependent endocytosis - Google Patents

Methods and agents for inhibiting dynamin-dependent endocytosis

Info

Publication number
GB2426517A
GB2426517A GB0612313A GB0612313A GB2426517A GB 2426517 A GB2426517 A GB 2426517A GB 0612313 A GB0612313 A GB 0612313A GB 0612313 A GB0612313 A GB 0612313A GB 2426517 A GB2426517 A GB 2426517A
Authority
GB
United Kingdom
Prior art keywords
dependent endocytosis
methods
agents
cells
dynamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0612313A
Other languages
English (en)
Other versions
GB0612313D0 (en
Inventor
Adam Mcclusky
Phillip J Robinson
Timothy Adrian Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Newcastle
Childrens Medical Research Institute
Newcastle Innovation Ltd
Original Assignee
The University of Newcastle
Childrens Medical Research Institute
Newcastle Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906456A external-priority patent/AU2003906456A0/en
Application filed by The University of Newcastle, Childrens Medical Research Institute, Newcastle Innovation Ltd filed Critical The University of Newcastle
Publication of GB0612313D0 publication Critical patent/GB0612313D0/en
Publication of GB2426517A publication Critical patent/GB2426517A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB0612313A 2003-11-21 2004-11-22 Methods and agents for inhibiting dynamin-dependent endocytosis Withdrawn GB2426517A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003906456A AU2003906456A0 (en) 2003-11-21 Methods and agents for inhibiting dynamin-mediated endocytosis
AU2003906823A AU2003906823A0 (en) 2003-12-09 Methods and agents for inhibiting dynamin-mediated endocytosis II
PCT/AU2004/001624 WO2005049009A1 (en) 2003-11-21 2004-11-22 Methods and agents for inhibiting dynamin-dependent endocytosis

Publications (2)

Publication Number Publication Date
GB0612313D0 GB0612313D0 (en) 2006-08-09
GB2426517A true GB2426517A (en) 2006-11-29

Family

ID=34620917

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0612313A Withdrawn GB2426517A (en) 2003-11-21 2004-11-22 Methods and agents for inhibiting dynamin-dependent endocytosis

Country Status (6)

Country Link
US (1) US20070225363A1 (https=)
EP (1) EP1691800A4 (https=)
JP (1) JP2007515399A (https=)
CA (1) CA2556801A1 (https=)
GB (1) GB2426517A (https=)
WO (1) WO2005049009A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5283962B2 (ja) * 2007-08-06 2013-09-04 国立大学法人 岡山大学 医薬組成物
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
GB2458259A (en) * 2008-02-05 2009-09-16 Univ Aberdeen Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
EP2432465B1 (en) 2009-05-21 2015-07-22 Children's Medical Research Institute Use of dynamin ring stabilizers
AU2013334493B2 (en) 2012-10-26 2018-11-29 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN109152777A (zh) * 2016-05-20 2019-01-04 武田药品工业株式会社 疼痛的治疗
US20230142547A1 (en) 2020-03-20 2023-05-11 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3884946A1 (en) 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
US12275941B2 (en) * 2021-04-15 2025-04-15 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of dynamin-1 variants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019169A2 (en) * 1994-01-07 1995-07-20 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor
WO1997013749A2 (en) * 1995-09-29 1997-04-17 Alliedsignal Inc. Novel cinnamamides and their use as stabilizers
US5892096A (en) * 1994-11-09 1999-04-06 Brewer Science, Inc. Non-subliming mid-UV dyes and ultra-thin organic arcs having differential solubility

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
GB9811692D0 (en) * 1998-06-01 1998-07-29 Medical Res Council Improvements in or relating to uptake of substances by cells
US20020076784A1 (en) * 2000-02-28 2002-06-20 Rachel Meyers 40322, a novel human dynamin
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019169A2 (en) * 1994-01-07 1995-07-20 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor
US5892096A (en) * 1994-11-09 1999-04-06 Brewer Science, Inc. Non-subliming mid-UV dyes and ultra-thin organic arcs having differential solubility
WO1997013749A2 (en) * 1995-09-29 1997-04-17 Alliedsignal Inc. Novel cinnamamides and their use as stabilizers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry, Vol. 10, No. 12, December 2002, (Yuan Hongbin; Parrill Abby L.), pages 4169 - 4183, ISSN 0968-0896 *
Journal of Medicinal Chemistry, Vol. 39, No. 25, 6 December 1996, (Gazit A; Osherov N; Gilon C; Levitzki A), pages 4905 - 4911, ISSN 0022-2623 *

Also Published As

Publication number Publication date
GB0612313D0 (en) 2006-08-09
WO2005049009A1 (en) 2005-06-02
US20070225363A1 (en) 2007-09-27
EP1691800A1 (en) 2006-08-23
JP2007515399A (ja) 2007-06-14
EP1691800A4 (en) 2009-03-18
CA2556801A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2330202A (en) Treatment of statin side effects
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
SI1664041T1 (sl) Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
WO2005019240A3 (en) Melanin concentrating hormone receptor antagonists
WO2004026293A3 (en) Hemiasterlin derivatives for treating resistant tumors
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
PL1664016T3 (pl) Środki terapeutyczne przydatne do leczenia bólu
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
MX2007013624A (es) Inhibidores de proteina cinasa.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DE69907419D1 (en) Antitumorwirkstoffe
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
TW200639159A (en) Treatment of pain
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
TW200742580A (en) Methods for treating nephrolithiasis
AU2368802A (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
MXPA05003909A (es) Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)